Reikes Peter N 4

What Happened

• Peter N. Reikes, a director of Ionis Pharmaceuticals (IONS), was granted 3,399 Restricted Stock Units (RSUs) on July 15, 2026. The grant is recorded as a derivative award (code A) at $0.00 per unit — there is no immediate cash purchase or sale in this transaction.

Key Details

• Transaction date: July 15, 2026; Form filed July 17, 2026 (appears timely).
• Award: 3,399 RSUs granted; reported price $0.00 (derivative award).
• Vesting: RSUs vest in three equal annual installments, first vesting on July 15, 2027; fully vested July 15, 2029. As of the grant date, 0 shares were vested.
• Payout: Upon vesting, units will be paid in whole shares of Ionis common stock or cash at the company’s discretion (footnote).
• Shares owned after transaction: Not disclosed in this filing.
• No 10b5-1 plan, tax withholding, or sale noted in the filing.

Context

• RSUs are a common form of director compensation intended to align directors’ interests with shareholders; they are not an immediate purchase signal. Because this is a grant (not a buy or sell), it reflects compensation rather than a direct market-confidence action by the insider.